Abstract
Diabetes mellitus is a strong risk factor for the development of cardiovascular disease, and is associated with a worse prognosis. The incidence of congestive heart failure is higher in diabetic patients, although the reasons for this increased rate are debated (higher incidence and severity of coronary heart disease and arterial hypertension, or a true diabetic cardiomyopathy). The treatment of heart failure in diabetic patients does not differ from that of non-diabetic patients, although recent studies of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers offer interesting new perspectives.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Adrenergic alpha-Antagonists / therapeutic use
-
Adrenergic beta-Antagonists / therapeutic use
-
Adult
-
Aged
-
Angiotensin II / antagonists & inhibitors
-
Angiotensin Receptor Antagonists
-
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
-
Antihypertensive Agents / therapeutic use
-
Carbazoles / therapeutic use
-
Cardiotonic Agents / therapeutic use
-
Carvedilol
-
Clinical Trials as Topic
-
Coronary Disease / complications
-
Diabetes Complications*
-
Diabetes Mellitus, Type 2 / complications
-
Female
-
Heart Failure / drug therapy*
-
Heart Failure / etiology
-
Heart Failure / mortality
-
Heart Failure / prevention & control*
-
Humans
-
Hypertension / complications
-
Hypertrophy, Left Ventricular / complications
-
Lisinopril / therapeutic use
-
Male
-
Meta-Analysis as Topic
-
Metoprolol / therapeutic use
-
Prognosis
-
Propanolamines / therapeutic use
-
Risk Factors
-
Time Factors
Substances
-
Adrenergic alpha-Antagonists
-
Adrenergic beta-Antagonists
-
Angiotensin Receptor Antagonists
-
Angiotensin-Converting Enzyme Inhibitors
-
Antihypertensive Agents
-
Carbazoles
-
Cardiotonic Agents
-
Propanolamines
-
Carvedilol
-
Angiotensin II
-
Lisinopril
-
Metoprolol